BidaskClub Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to “Sell”

BidaskClub upgraded shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) from a strong sell rating to a sell rating in a research report released on Wednesday, BidAskClub reports.

Several other equities research analysts have also issued reports on RYTM. Zacks Investment Research lowered Rhythm Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, July 17th. LADENBURG THALM/SH SH reaffirmed a buy rating and set a $43.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, September 9th. Stifel Nicolaus reaffirmed a buy rating and set a $34.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, July 29th. Canaccord Genuity began coverage on Rhythm Pharmaceuticals in a research note on Monday, July 8th. They set a buy rating and a $35.00 price target for the company. Finally, ValuEngine raised Rhythm Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. Rhythm Pharmaceuticals has a consensus rating of Buy and a consensus price target of $38.80.

Shares of RYTM stock opened at $24.51 on Wednesday. The company has a quick ratio of 7.80, a current ratio of 7.80 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average price of $21.56 and a two-hundred day moving average price of $24.20. Rhythm Pharmaceuticals has a 12-month low of $18.00 and a 12-month high of $32.62.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Monday, July 29th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.36). On average, sell-side analysts forecast that Rhythm Pharmaceuticals will post -4.16 EPS for the current year.

Hedge funds have recently modified their holdings of the business. Point72 Hong Kong Ltd bought a new stake in Rhythm Pharmaceuticals during the second quarter worth about $31,000. Marshall Wace North America L.P. purchased a new position in shares of Rhythm Pharmaceuticals in the first quarter worth about $33,000. Bank of Montreal Can increased its holdings in shares of Rhythm Pharmaceuticals by 194,200.0% in the second quarter. Bank of Montreal Can now owns 1,943 shares of the company’s stock worth $43,000 after buying an additional 1,942 shares during the period. BNP Paribas Arbitrage SA increased its holdings in shares of Rhythm Pharmaceuticals by 105,433.3% in the first quarter. BNP Paribas Arbitrage SA now owns 3,166 shares of the company’s stock worth $87,000 after buying an additional 3,163 shares during the period. Finally, Tiff Advisory Services Inc. purchased a new position in shares of Rhythm Pharmaceuticals in the first quarter worth about $217,000. 90.58% of the stock is owned by hedge funds and other institutional investors.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.

Featured Article: What are some reasons analysts would give stocks a buy rating?

Analyst Recommendations for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit